CASI Pharmaceuticals Files April 2025 6-K Report
Ticker: CASIF · Form: 6-K · Filed: Apr 3, 2025 · CIK: 1962738
| Field | Detail |
|---|---|
| Company | Casi Pharmaceuticals, INC. (CASIF) |
| Form Type | 6-K |
| Filed Date | Apr 3, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, foreign-private-issuer, press-release
TL;DR
CASI Pharma dropped an April 6-K, check the press release for deets.
AI Summary
CASI Pharmaceuticals, Inc. filed a Form 6-K on April 3, 2025, reporting information for the month of April 2025. The filing includes a press release dated April 3, 2025, as Exhibit 99.1. The company's principal executive office is located in Beijing, People's Republic of China.
Why It Matters
This filing provides an update on CASI Pharmaceuticals' activities and disclosures for April 2025, which is important for investors to stay informed about the company's ongoing operations and any material information released.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer and does not contain significant new financial or operational information that would immediately impact risk.
Key Players & Entities
- CASI Pharmaceuticals, Inc. (company) — Registrant
- April 3, 2025 (date) — Filing date and press release date
- Beijing, People's Republic of China (location) — Principal executive office location
FAQ
What type of report is CASI Pharmaceuticals filing?
CASI Pharmaceuticals, Inc. is filing a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934.
What is the filing date of this Form 6-K?
The Form 6-K was filed on April 3, 2025.
Where is CASI Pharmaceuticals, Inc. located?
The company's principal executive office is located at 1701-1702, China Central Office Tower 1, No. 81 Jianguo Road, Chaoyang District, Beijing, 100025, People's Republic of China.
What exhibits are included in this filing?
The filing includes Exhibit No. 99.1, which is a Press Release of CASI Pharmaceuticals, Inc. dated April 3, 2025.
Does CASI Pharmaceuticals file annual reports under Form 20-F or 40-F?
The filing indicates that the registrant files annual reports under Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 3, 2025 regarding CASI Pharmaceuticals, Inc. (CASIF).